The goal of this protocol is to manufacture pathogen-specific clinical-grade T cells using a bench-top, automated, second generation cell enrichment device that incorporates a closed cytokine capture system and does not require dedicated staff or use of a GMP facility. The cytomegalovirus pp65-specific-T cells generated can be directly administered to patients.
Kumaresan, P., Figliola, M., Moyes, J. S., Huls, M. H., Tewari, P., Shpall, E. J., Champlin, R., Cooper, L. J. Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. J. Vis. Exp. (104), e52808, doi:10.3791/52808 (2015).